BC Innovations | Feb 1, 2019
Product R&D

BlueRock’s PD purity play

Regenerative medicine company BlueRock is gearing up to submit its first IND this year, banking on its approach to Parkinson’s disease to overcome the legacy of failed fetal transplants by offering a more stable and...
BC Week In Review | Nov 17, 2017
Clinical News

International Stem Cell reports interim Phase I data for PD stem cell treatment

International Stem Cell Corp. (OTCQB:ISCO) reported interim 6-month data from the first cohort of patients in a Phase I trial to treat Parkinson's disease showing that 30 million human parthenogenetic stem cell (hpSC)-derived neuronal cells...
BC Innovations | May 5, 2016
Product R&D

Cell therapy's yada yada yada

The novel science and dramatic clinical results behind chimeric antigen receptor (CAR) T cells and other cell therapies have the technology labeled by many as one of the most promising advances in biotech. But away...
BC Week In Review | Mar 14, 2016
Financial News

International Stem Cell completes private placement of convertible preferred stock and warrants

International Stem Cell Corp. (OTCQB:ISCO), Carlsbad, Calif.   Business: Gene/Cell therapy, Transplant   Date completed: 2016-03-10   Type: Private placement of convertible preferred stock and warrants   Raised: $2.5 million   Shares: 6,310   Price:...
BC Week In Review | Mar 14, 2016
Clinical News

HpNSCs: Phase I started

International Stem Cell began an open-label, dose-escalation, Australian Phase I trial to evaluate 3 dose levels of 30-70 million hpSC-derived neuronal cells injected intracerebrally into the striatum and substantia nigra of about 12 patients. International...
BC Innovations | Mar 10, 2016
Tools & Techniques

Ziopharm bets on the HLA-A odds

Ziopharm Oncology Inc. is adding gene editing to its repertoire with a strategy to increase the odds of finding a match for hematopoietic stem cell transplants. While the system is still short of an allogeneic...
BC Week In Review | Dec 21, 2015
Financial News

International Stem Cell amends private placement of units

International Stem Cell Corp. (OTCQB:ISCO), Carlsbad, Calif.   Business: Gene/Cell therapy, Transplant   Date announced: 2015-12-14   Type: Private placement of units   To be raised: Up to $10 million   Units: TBD   Price...
BC Week In Review | Dec 7, 2015
Financial News

International Stem Cell amends private placement of units

International Stem Cell Corp. (OTCQB:ISCO), Carlsbad, Calif.   Business: Gene/Cell therapy, Transplant   Date announced: 2015-11-25   Type: Private placement of units   To be raised: Up to $6 million   Units: TBD   Price...
BC Week In Review | Jun 29, 2015
Financial News

International Stem Cell proposes private placement of common stock and warrants

International Stem Cell Corp. (OTCQB:ISCO), Carlsbad, Calif.   Business: Gene/Cell therapy, Transplant   Date announced: 2015-06-24   Type: Private placement of common stock and warrants   To be raised: Up to $6 million   Shares:...
BC Innovations | Feb 19, 2015
Product R&D

Banking on stem cells

While stem cell developers wrestle with fine-tuning cell types, improving protocols and calling for better regulatory guidelines, few in the field are addressing one of the looming problems likely to hit once more products reach...
Items per page:
1 - 10 of 52
BC Innovations | Feb 1, 2019
Product R&D

BlueRock’s PD purity play

Regenerative medicine company BlueRock is gearing up to submit its first IND this year, banking on its approach to Parkinson’s disease to overcome the legacy of failed fetal transplants by offering a more stable and...
BC Week In Review | Nov 17, 2017
Clinical News

International Stem Cell reports interim Phase I data for PD stem cell treatment

International Stem Cell Corp. (OTCQB:ISCO) reported interim 6-month data from the first cohort of patients in a Phase I trial to treat Parkinson's disease showing that 30 million human parthenogenetic stem cell (hpSC)-derived neuronal cells...
BC Innovations | May 5, 2016
Product R&D

Cell therapy's yada yada yada

The novel science and dramatic clinical results behind chimeric antigen receptor (CAR) T cells and other cell therapies have the technology labeled by many as one of the most promising advances in biotech. But away...
BC Week In Review | Mar 14, 2016
Financial News

International Stem Cell completes private placement of convertible preferred stock and warrants

International Stem Cell Corp. (OTCQB:ISCO), Carlsbad, Calif.   Business: Gene/Cell therapy, Transplant   Date completed: 2016-03-10   Type: Private placement of convertible preferred stock and warrants   Raised: $2.5 million   Shares: 6,310   Price:...
BC Week In Review | Mar 14, 2016
Clinical News

HpNSCs: Phase I started

International Stem Cell began an open-label, dose-escalation, Australian Phase I trial to evaluate 3 dose levels of 30-70 million hpSC-derived neuronal cells injected intracerebrally into the striatum and substantia nigra of about 12 patients. International...
BC Innovations | Mar 10, 2016
Tools & Techniques

Ziopharm bets on the HLA-A odds

Ziopharm Oncology Inc. is adding gene editing to its repertoire with a strategy to increase the odds of finding a match for hematopoietic stem cell transplants. While the system is still short of an allogeneic...
BC Week In Review | Dec 21, 2015
Financial News

International Stem Cell amends private placement of units

International Stem Cell Corp. (OTCQB:ISCO), Carlsbad, Calif.   Business: Gene/Cell therapy, Transplant   Date announced: 2015-12-14   Type: Private placement of units   To be raised: Up to $10 million   Units: TBD   Price...
BC Week In Review | Dec 7, 2015
Financial News

International Stem Cell amends private placement of units

International Stem Cell Corp. (OTCQB:ISCO), Carlsbad, Calif.   Business: Gene/Cell therapy, Transplant   Date announced: 2015-11-25   Type: Private placement of units   To be raised: Up to $6 million   Units: TBD   Price...
BC Week In Review | Jun 29, 2015
Financial News

International Stem Cell proposes private placement of common stock and warrants

International Stem Cell Corp. (OTCQB:ISCO), Carlsbad, Calif.   Business: Gene/Cell therapy, Transplant   Date announced: 2015-06-24   Type: Private placement of common stock and warrants   To be raised: Up to $6 million   Shares:...
BC Innovations | Feb 19, 2015
Product R&D

Banking on stem cells

While stem cell developers wrestle with fine-tuning cell types, improving protocols and calling for better regulatory guidelines, few in the field are addressing one of the looming problems likely to hit once more products reach...
Items per page:
1 - 10 of 52